4 results
The purpose of the study is to investigate how quickly and to what extent rivastigmine is absorbed and eliminated from the body when administered RTS for 7 days (this is called pharmacokinetics) as well as the safety of RTS.
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.
To compare the feasibility and safety of surface cooling to 34, 34.5, and 35*C, started within 4.5 hours after the onset of acute ischaemic stroke and maintained for 24 hours, in awake patients on a stroke unit.
To compare the rate and extent of rivastigmine absorption from two different formulations of 7-day rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patch applied daily for 7 days in healthy adult male and female subjects.To assess…